[1] Niyazy M M. The role of FAT MASS and obesity association locus “Fto” gene polymorphism in susceptibility to development of type 2 diabetes and obesity in selected Sudanese population[D].Khartoum:University of Khartoum,2015. [2] McClung M R, Wagman R B, Miller P D, et al. Observations following discontinuation of long-term denosumab therapy[J]. Osteoporos Int, 2017, 28(5): 1723-1732. [3] 易伟莲, 廖德权, 林柏云, 等. 绝经后骨质疏松症患者性激素、细胞因子及骨代谢指标的变化及关系[J]. 检验医学, 2012, 27(4): 296-298. [4] 徐伟丽, 牛玲玲, 王文侠, 等. 经典Wnt信号通路对骨代谢的调节作用[J]. 中国骨质疏松杂志, 2016, 22(3): 376-380. [5] You H F, Zhao J Z, Zhai Y J, et al. Association between low-density lipoprotein receptor-related protein 5 polymorphisms and type 2 diabetes mellitus in Han Chinese: a case-control study[J]. Biomed Environ Sci, 2015, 28(7): 510-517. [6] 渠昕, 楚淑芳, 赵恒侠, 等. 滋肾降糖丸对肾阴虚证2型糖尿病患者血清硬化蛋白的影响[J]. 新中医, 2018, 50(5): 51-54. [7] Gaudio A, Privitera F, Pulvirenti I, et al. The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus[J]. Diab Vasc Dis Res, 2014, 11(1): 48-52. [8] Alberti K G, Zimmet P Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation[J]. Diabet Med,1998,15(7):539-553. [9] Kanis J A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group[J].Osteoporos Int,1994,4(6):368-381. [10] Mohd-Tahir N A, Li S C. Economic burden of osteoporosis-related hip fracture in Asia: a systematic review[J]. Osteoporos Int, 2017, 28(7): 2035-2044. [11] Raška I Jr, Rašková M, Zikán V, et al. Prevalence and risk factors of osteoporosis in postmenopausal women with type 2 diabetes mellitus[J]. Cent Eur J Public Health, 2017, 25(1): 3-10. [12] Bonaccorsi G, Messina C, Cervellati C, et al. Fracture risk assessment in postmenopausal women with diabetes: comparison between DeFRA and FRAX tools[J]. Gynecol Endocrinol, 2018, 34(5): 404-408. [13] Astiazarán M C, Cervantes-Sodi M, Rebolledo-Enríquez E, et al. Novel homozygous LRP5 mutations in Mexican patients with osteoporosis-pseudoglioma syndrome[J]. Genet Test Mol Biomarkers, 2017, 21(12): 742-746. [14] Uitterlinden A G, Arp P P, Paeper B W, et al. Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites[J]. Am J Hum Genet, 2004, 75(6): 1032-1045. [15] Balemans W, Foernzler D, Parsons C, et al. Lack of association between the SOST gene and bone mineral density in perimenopausal women: analysis of five polymorphisms[J]. Bone, 2002, 31(4): 515-519. [16] Bijelic R, Balaban J, Milicevic S. Correlation of the lipid profile, BMI and bone mineral density in postmenopausal women[J]. Mater Sociomed, 2016, 28(6): 412-415. [17] Wang J J, Yan G L, Zhang J F, et al. Association of LRP5, TCF7L2, and GCG variants and type 2 diabetes mellitus as well as fasting plasma glucose and lipid metabolism indexes[J]. Hum Immunol, 2015, 76(5): 339-343. [18] Piters E, De Freitas F, Nielsen T L, et al. Association study of polymorphisms in the SOST gene region and parameters of bone strength and body composition in both young and elderly men: data from the Odense Androgen Study[J]. Calcif Tissue Int, 2012, 90(1): 30-39. |